entity

APP pathway

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about APP pathway: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections
1Hypotheses
1Analyses
1Outgoing
0Incoming
2Experiments
2Debates

No AI portrait yet

Outgoing (1)

TargetRelationTypeStr
Alzheimer's diseasetherapeutic_target_fordisease0.70

Incoming (0)

SourceRelationTypeStr
No incoming edges

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Selective Cholinergic Protection via APP Pathway Modulation 0.629 neurodegeneration Clinical Trial Landscaping for Alzheimer

Mentioning Analyses (1)

Scientific analyses that reference this entity

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.629

Experiments (2)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
Plasma ATN biomarkers across AD continuum in Chilean cohort clinical Alzheimer's disease 0.950 0.00 Chilean older adults (n=318) w proposed N/A
Adoptive transfer of TCRAβ-Tregs in AD mouse model validation Alzheimer's disease 0.900 0.00 transgenic mice expressing chi proposed N/A

Related Papers (12)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Cataract Aggravates Alzheimer-Like Pathologies and Cognitive Deficits in an APP/ [PMID:40580389] Geng Z, Yu ZY, Tan J, Wang XY, Zeng GH e Neurosci Bull 2026 0
HOPS disruption impairs APP trafficking and processing, promoting exosomal secre [PMID:41525887] Draper D, George AE, Veenendaal T, van D Neurobiol Dis 2026 0
TREM2 expression level is critical for microglial state, metabolic capacity and [PMID:41580393] Feiten AF, Dahm K, Schlepckow K, van Len Nat Commun 2026 0
APP-C31 pathology as a target in neurodegenerative diseases. [PMID:41639863] Yip KC, Ho WF, Liu Y, Dawe GS J Biomed Sci 2026 0
Decoding Alzheimer's disease through down syndrome: insights from a genetically [PMID:41709686] Russell JK, Schlachetzki Z, Rafii MS Curr Opin Neurol 2026 0
Apps for people with vision impairment: an international review of practitioner [PMID:41734772] Gothwal VK, Miller A, Boon MY, Subramani Clin Exp Optom 2026 0
Impaired TGFβ Signaling in Plaque-Associated Microglia. [PMID:41750318] Krzyzan O, Kuhla A, Spittau B, Vidovic N Biomolecules 2026 0
APP as an innate injury-response molecule. [PMID:41864298] Olmsted ZT, Sofroniew MV Neurobiol Dis 2026 0
CRISPR-Cas9 and next-generation gene editing strategies for therapeutic interven [PMID:41931258] Khan MS, Zafar I, Jamal A, Bahwerth FS, Acta Neurol Belg 2026 0
Akkermansia muciniphila reduces neuroinflammation and Aβ deposition via tryptoph [PMID:41715194] Wang B, Pan M, Yang L, Xu J, Ye C, Li Y, Alzheimer's research & therapy 2026 0
Alzheimer's disease basics: we all should know. [PMID:40639927] Das S Neurological research 2026 0
Cerebral FURIN deficiency impairs astrocytic lipophagy through ITGAV maturation. [PMID:41376284] Xie XY, Wang L, Xie SQ, Zhou GF, Wen QX, Autophagy 2026 0

Debates (2)

Multi-agent debates referencing this entity

What is the current clinical trial landscape for AD therapeutics, and which mech

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Is the amyloid concentration in AD clinical trials rational given lecanemab's ap

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Related Research

Hypotheses and analyses mentioning APP pathway in their description or question text

No additional research found